{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:17:20Z","timestamp":1794953840120,"version":"4.9.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.isci.2026.116938","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:57:19Z","timestamp":1784883439000},"page":"116938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Encapsulated cell therapy for local anti-CTLA-4 delivery in cancer immunotherapy"],"prefix":"10.1016","volume":"29","author":[{"given":"Adrien","family":"Engel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Vernet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Charrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Urwyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Von Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Saingier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Courtout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Abukscem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bouvarel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelien","family":"Lathuiliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davy","family":"Guillarme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Grogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.116938_bib1","doi-asserted-by":"crossref","first-page":"e27614","DOI":"10.4161\/onci.27614","article-title":"Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo","volume":"3","author":"Sandin","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.isci.2026.116938_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.isci.2026.116938_bib3","doi-asserted-by":"crossref","first-page":"59682","DOI":"10.1021\/acsami.4c12603","article-title":"Emerging Strategies for Local Delivery of Immune Checkpoint Inhibitors to Potentiate Cancer Immunotherapy: Current Status and Future Prospects","volume":"16","author":"Chen","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.isci.2026.116938_bib4","article-title":"Emerging Technologies for Local Cancer Treatment","volume":"3","author":"Chua","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.isci.2026.116938_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.04.018","article-title":"Cell encapsulation: Overcoming barriers in cell transplantation in diabetes and beyond","volume":"139","author":"Farina","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.isci.2026.116938_bib6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tips.2015.05.003","article-title":"Cell encapsulation: technical and clinical advances","volume":"36","author":"Orive","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.isci.2026.116938_bib7","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116938_bib8","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116938_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116938_bib10","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","article-title":"Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.116938_bib11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1\/Anti-CTLA-4 Combined Therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.116938_bib12","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.116938_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.isci.2026.116938_bib14","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","article-title":"Anti-CTLA-4 immunotherapy does not deplete Foxp3 \u00fe regulatory T cells (Tregs) in human cancers","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116938_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2026.116938_bib16","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.116938_bib17","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","article-title":"Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma","volume":"57","author":"Kleiner","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.isci.2026.116938_bib18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.116938_bib19","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1021\/acs.nanolett.5b05030","article-title":"Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody","volume":"16","author":"Wang","year":"2016","journal-title":"Nano Lett."},{"key":"10.1016\/j.isci.2026.116938_bib20","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-12-0781","article-title":"Controlled local delivery of CTLA-4 blocking antibody induces CD8 + T-cell-dependent tumor eradication and decreases risk of toxic side effects","volume":"19","author":"Fransen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116938_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/1535-7163.MCT-21-0234","article-title":"Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs","volume":"21","author":"Gilardi","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2026.116938_bib22","first-page":"A300","article-title":"277 Safety and efficacy of intratumoral ipilimumab with IV nivolumab in metastatic melanoma. The NIVIPIT trial","volume":"9","author":"Tselikas","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.116938_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005224","article-title":"Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: The phase 1b MITCI study","volume":"10","author":"Curti","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.116938_bib24","first-page":"A823","article-title":"790 Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1) +\/CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and AS01 B in combination with intravenously administered nivolumab","volume":"10","author":"Tijtgat","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.116938_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41565-018-0319-4","article-title":"In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment","volume":"14","author":"Chen","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.isci.2026.116938_bib26","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","article-title":"Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets","volume":"5","author":"Hu","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.isci.2026.116938_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002296","article-title":"Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: A phase i clinical trial","volume":"9","author":"Duerinck","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.116938_bib28","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/brain\/aww036","article-title":"A subcutaneous cellular implant for passive immunization against amyloid-\u03b2 reduces brain amyloid and tau pathologies","volume":"139","author":"Lathuili\u00e8re","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.isci.2026.116938_bib29","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41551-020-0538-5","article-title":"A retrievable implant for the long-term encapsulation and survival of therapeutic xenogeneic cells","volume":"4","author":"Bose","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.isci.2026.116938_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107372","article-title":"Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins","volume":"26","author":"Grogg","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.isci.2026.116938_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.omtm.2022.07.017","article-title":"Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology","volume":"26","author":"Lathuiliere","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.isci.2026.116938_bib32","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.biomaterials.2013.09.071","article-title":"A high-capacity cell macroencapsulation system supporting the long-term survival of genetically engineered allogeneic cells","volume":"35","author":"Lathuili\u00e8re","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.isci.2026.116938_bib33","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.116938_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/eji.201646583","article-title":"Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer","volume":"47","author":"van Hooren","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.isci.2026.116938_bib35","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2005-06-2298","article-title":"Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies","volume":"106","author":"Lute","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116938_bib36","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2007-11-125435","article-title":"CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion","volume":"112","author":"Kavanagh","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116938_bib37","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1172\/JCI27745","article-title":"CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells","volume":"116","author":"Quezada","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.116938_bib38","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2767-9764.CRC-24-0150","article-title":"A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors","volume":"4","author":"Vernet","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.isci.2026.116938_bib39","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3109\/07388551.2015.1084266","article-title":"Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives","volume":"36","author":"Dumont","year":"2016","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.isci.2026.116938_bib40","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0161-5890(01)00025-6","article-title":"Role of natural and immune IgM antibodies in immune responses","volume":"37","author":"Boes","year":"2000","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.isci.2026.116938_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35629-z","article-title":"Implantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal in rats","volume":"13","author":"Paez-Mayorga","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.116938_bib42","doi-asserted-by":"crossref","first-page":"10578","DOI":"10.3390\/ijms160510578","article-title":"Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system","volume":"16","author":"Lathuili\u00e8re","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.116938_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2021.10.044","article-title":"Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models","volume":"545","author":"Huang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.isci.2026.116938_bib44","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200879119","article-title":"An anti-CTLA-4 heavy chain-only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile","volume":"119","author":"Gan","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.116938_bib45","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s00262-022-03170-z","article-title":"Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy","volume":"71","author":"Sato","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.isci.2026.116938_bib46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41422-018-0012-z","article-title":"Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.isci.2026.116938_bib47","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.116938_bib48","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/ijc.23001","article-title":"Functional and phenotypic characteristics of CD4+CD25 highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer","volume":"121","author":"Strauss","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.isci.2026.116938_bib49","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1146\/annurev-immunol-020711-075043","article-title":"Induced CD4 +Foxp3 + regulatory T cells in immune tolerance","volume":"30","author":"Bilate","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.116938_bib50","doi-asserted-by":"crossref","first-page":"e0217276","DOI":"10.1371\/journal.pone.0217276","article-title":"Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice","volume":"14","author":"Affolter","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.116938_bib51","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.194.4.481","article-title":"Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy","volume":"194","author":"Van Elsas","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.116938_bib52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-015-0063-3","article-title":"NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade","volume":"3","author":"Kohlhapp","year":"2015","journal-title":"J. Immunother. Cancer"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226023163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226023163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:42:24Z","timestamp":1794951744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226023163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2589004226023163"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.116938","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Encapsulated cell therapy for local anti-CTLA-4 delivery in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.116938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116938"}}